Chang WI, Kim BH, Kim YJ, et al. - In Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) patients who were treated with sorafenib, locoregional radiation therapy (RT) conferred a significantly longer survival. Thus, the dismal prognosis in these patients could be improved by incorporating locoregional RT.

• A retrospective review of 398 patients treated with sorafenib for BCLC stage C HCC; 68 (17.1%) patients received locoregional RT.

• Median progression-free survival and overall survival (OS) of 2.2 and 9.5 months, respectively, were obtained.

• Multivariate analysis showed a favorable OS in relation to locoregional RT.

• Following 1:1 propensity score matching, a worse OS was observed in patients who did not receive locoregional RT vs those treated with RT (median 9.6 months vs 15.7 months).

• No prolongation of OS was achieved with locoregional RT before/concurrent with sorafenib, whereas significantly prolonged OS was conferred by locoregional RT after sorafenib vs sorafenib without locoregional RT.

• Locoregional RT proved to be significantly beneficial for patients treated with ≥12 weeks of sorafenib.